businessbriefs
12:05in productionCh. 1 · The Prescription Imperative/ 12:05 · ceiling 15 min
Companies

Eli Lilly and Company

Eli Lilly · 1875

Lilly didn’t just make insulin — it built the machinery that turned medicine into a regulated, prescription-gated, quality-assured industry.

Eli Lilly and Company is a foundational case in how business infrastructure — not just discovery — creates pharmaceutical power. Its early bets on quality control, prescription gatekeeping, and regulation were deliberate, profitable, and durable. The sources confirm no modern financials or valuations, so analysis must stay anchored in its documented methods and milestones.

CompaniesMedicineScientific methodVaccinesMedicine across the network →
Chapters & takeaways6
  1. 1:26
    The Prescription Imperative

    Lilly founded the company in 1876 in Indianapolis to replace ineffective patent medicines with scientifically manufactured prescription drugs.

  2. 2:52
    Manufacturing Rigour

    It staffed the first dedicated research department, invented gelatin capsules, added fruit flavourings, and sold wholesale to pharmacies — not consumers.

  3. 3:54
    Insulin as Infrastructure

    Iletin (1923) was its breakthrough: the first commercially available insulin in the US, mass-produced by Lilly — the drug that made it a global manufacturer.

  4. 5:30
    Scale Before Science

    Quinine delivered a tenfold sales increase; the firm’s success came from scalable, high-quality production — not novelty alone.

  5. 6:24
    Regulation as Strategy

    Lilly helped create the prescription system and lobbied for the 1906 law that led to the FDA — turning regulation into competitive advantage.

  6. 8:04
    Mass Production First

    It was the first to mass-produce both insulin and the Salk polio vaccine — proving its industrial capacity long before biotech existed.

Worth your time?

Yes. Study the whole thing.

4.5/ 5
What works
  • prescription system design
  • regulatory advocacy as leverage
  • industrial scaling of biologics
What does not
  • current revenue
  • valuation
  • headcount
  • market share
Study it if
  • historians of industry
  • health policy analysts
  • pharma operations strategists
Skip it if
  • investors seeking financial metrics
  • biotech founders looking for innovation playbooks
  • consumers evaluating drug access
The written brief1 min read

What the company or idea is

Eli Lilly and Company is an American multinational pharmaceutical company founded in 1876 in Indianapolis. It pioneered scientific drug manufacturing, prescription-only distribution, and federal regulation of medicines.

How it actually makes money

Lilly manufactures drugs and sells them wholesale to pharmacies. It does not sell directly to patients or rely on retail branding.

What works

Insulin — sold as Iletin from 1923 — was the most important drug in its history and did more than any other to make Lilly a major global manufacturer. Quinine sales increased tenfold. Its early commitment to high-quality, physician-restricted medicines differentiated it from patent-medicine competitors.

What does not

The sources say nothing about current revenue, margins, market share, valuation, headcount, or recent drug approvals. No claims can be made about its present-day scale, profitability, or pipeline beyond what is verified.

What to take from it

Its success came not from invention alone but from system-building: dedicated research departments, gelatin capsules, fruit flavourings, quality assurance, and lobbying for the 1906 law that created the FDA.

Is it worth your time

Yes — as a case study in how early methodical quality control, prescription gatekeeping, and regulatory advocacy shaped the modern pharmaceutical industry’s economic and ethical infrastructure.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Acquisition of Twitter by Elon Musk

2022 · 9:24

A hostile takeover that erased a public company, halved its staff twice over, and replaced governance with ultimatums — all before shipping one stated goal.

Play nextBack to Companies
9:24